Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 21 · below the Ichimoku cloud · RSI 34 · MACD below its signal
None of the 29 investors followed here reported a position in CBIO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CBIO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 15, 2026 | Fairmount Funds Management LlcBeneficial Owner of more than 10% of a Class of Security | Purchase at price 14.50 per share. | 853.5K | $12.38M |
| Jun 21, 2026 | Brumm Joshua T.Chief Executive Officer | Sale at price 17.99 per share. | 42.3K | $761.07K |
| Jun 21, 2026 | Lynch RyanOfficer and Treasurer | Sale at price 17.99 per share. | 465 | $8.37K |
| Jun 21, 2026 | Scalzo Richard WilliamChief Financial Officer | Sale at price 17.99 per share. | 1.1K | $20.00K |
| Jun 21, 2026 | Mcneill JonathanPresident | Sale at price 17.99 per share. | 20.5K | $369.68K |
| Jun 21, 2026 | Im Ellie EunkyungOfficer | Sale at price 17.99 per share. | 1.2K | $21.93K |
| Jun 21, 2026 | Bispham Barbara HarlinGeneral Counsel | Sale at price 17.99 per share. | 1.2K | $21.91K |
| Jun 21, 2026 | Pinkas JanOfficer | Sale at price 17.99 per share. | 1.3K | $23.17K |
| Dec 14, 2025 | Brumm Joshua T.Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 55.1K | — |
| Dec 14, 2025 | Lynch RyanOfficer and Treasurer | Stock Award(Grant) at price 0.00 per share. | 12.4K | — |
| Dec 14, 2025 | Scalzo Richard WilliamChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 19.4K | — |
| Dec 14, 2025 | Mcneill JonathanPresident | Stock Award(Grant) at price 0.00 per share. | 25.5K | — |
| Dec 14, 2025 | Doughty Christopher GrantOfficer | Stock Award(Grant) at price 0.00 per share. | 22.7K | — |
| Dec 14, 2025 | Im Ellie EunkyungOfficer | Stock Award(Grant) at price 0.00 per share. | 21.3K | — |
| Dec 14, 2025 | Bispham Barbara HarlinGeneral Counsel | Stock Award(Grant) at price 0.00 per share. | 18.4K | — |
| Dec 14, 2025 | Pinkas JanOfficer | Stock Award(Grant) at price 0.00 per share. | 22.5K | — |
| Dec 3, 2025 | Fairmount Funds Management LlcDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 13.41 per share. | 1.36M | $18.24M |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -19.1 | 26.1 | 51.9 | 21.8 | -7.7 | -12.8 | -19.6 | 14.7 | -12.1 | -11.5 | +8.9% | ||
| 2025 | 8.0 | 0.0 | -22.2 | 19.0 | -16.0 | -23.1 | -23.0 | 15.9 | -17.4 | 7.2 | 18.0 | -21.2 | −52.6% |
| 2024 | 27.1 | -3.7 | 3.8 | -40.0 | -85.0 | 3.7 | -21.4 | -18.2 | -5.6 | 141.2 | -14.6 | -28.6 | −89.4% |
| 2023 | -4.0 | -47.1 | -18.2 | 11.1 | 32.9 | -6.5 | -5.7 | -2.4 | -6.3 | -16.7 | 31.2 | 43.9 | −22.1% |
| 2022 | -17.4 | 3.4 | -7.3 | -36.8 | -6.9 | -10.4 | 10.0 | 15.2 | -27.6 | 23.6 | 217.6 | 40.3 | +110.4% |
| 2021 | -3.5 | -8.5 | -9.3 | -20.3 | 6.3 | -9.0 | -12.9 | 9.9 | -1.4 | -12.8 | -11.5 | -14.8 | −61.7% |
| 2020 | -19.1 | -15.4 | -37.0 | 22.4 | 1.4 | 32.9 | 4.8 | -6.3 | -16.8 | -8.8 | 34.3 | 0.0 | −28.9% |
| 2019 | 18.3 | 9.7 | 1.4 | -2.3 | -2.7 | 0.7 | -22.6 | -63.9 | 29.4 | 22.5 | 11.4 | -10.0 | −44.1% |
| 2018 | 33.9 | 2.3 | -29.5 | 4.1 | 5.8 | -9.7 | -8.9 | 0.2 | -2.2 | -12.6 | -8.7 | -17.6 | −43.6% |
| 2017 | -6.7 | 7.4 | -11.1 | -20.8 | 195.1 | -12.1 | 2.3 | 6.8 | 14.7 | -17.8 | 22.7 | 19.0 | +175.2% |
| 2016 | -17.7 | -3.6 | 31.3 | 5.7 | 30.8 | -11.8 | 14.9 | -11.3 | -3.5 | -15.7 | 5.3 | -3.9 | +6.6% |
| 2015 | 2.2 | 13.0 | 0.0 | -0.4 | -3.9 | -0.3 | -3.6 | -8.5 | -20.1 | 17.7 | 5.9 | -18.1 | −20.6% |
| 2014 | 22.5 | 34.0 | -18.7 | -46.0 | 17.7 | -2.8 | -0.5 | -14.8 | 2.7 | 35.8 | -25.6 | −27.6% |
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Buy / hold / sell counts